Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 11:53 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1225–1248 of 1,385 matching trials from the live ClinicalTrials.gov search.
Conditions
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Interventions
Blinatumomab, Standard of Care Chemotherapy
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
16
States / cities
Duarte, California • Los Angeles, California • San Francisco, California + 12 more
Conditions
Breast Cancer
Interventions
filgrastim, monoclonal antibody m170, cyclosporine, paclitaxel, peripheral blood stem cell transplantation, yttrium Y 90 monoclonal antibody m170
Biological · Drug · Procedure + 1 more
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Sacramento, California
Conditions
Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Grade 3 Follicular Lymphoma, Contiguous Stage II Marginal Zone Lymphoma, Contiguous Stage II Small Lymphocytic Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Splenic Marginal Zone Lymphoma, Stage I Grade 1 Follicular Lymphoma, Stage I Grade 2 Follicular Lymphoma, Stage I Grade 3 Follicular Lymphoma, Stage I Marginal Zone Lymphoma, Stage I Small Lymphocytic Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Small Lymphocytic Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Small Lymphocytic Lymphoma
Interventions
pegfilgrastim, rituximab, flow cytometry, biopsy, immunohistochemistry staining method, western blotting
Biological · Other · Procedure + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
19 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Acute Myocardial Infarction
Interventions
Filgrastim
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Multiple Myeloma
Interventions
Bortezomib, Granulocyte colony-stimulating factor (G-CSF), Mozobil
Drug
Lead sponsor
Siddhartha Ganguly
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Westwood, Kansas
Conditions
Leukemia
Interventions
filgrastim, cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, etoposide, ifosfamide, leucovorin calcium, mesna, methotrexate, therapeutic hydrocortisone, vincristine sulfate, low-LET cobalt-60 gamma ray therapy, low-LET photon therapy
Biological · Drug · Radiation
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Sarcoma
Interventions
filgrastim, ifosfamide, peripheral blood stem cell transplantation, Sm-EDTMP (low dose), sm-EDTMP (higher dose)
Biological · Drug · Procedure + 1 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
13 Years to 50 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Ewing's Sarcoma, Rhabdomyosarcoma
Interventions
EF-1 Peptide, EF-2 Peptide, PXFK Peptide, E7 Peptide, IL-2, IL-4, GM-CSF, CD40 Ligand
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 30 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Sarcoma
Interventions
celecoxib, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, vinblastine sulfate, vincristine sulfate, conventional surgery, radiation therapy, MESNA, Filgrastim
Drug · Procedure · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 50 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
87
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 78 more
Conditions
Brain and Central Nervous System Tumors, Kidney Cancer, Liver Cancer, Retinoblastoma, Sarcoma
Interventions
filgrastim, busulfan, etoposide, ifosfamide, melphalan, thiotepa, stem cell transplantation, tomotherapy, total marrow irradiation, Mesna, Whole lung radiation
Biological · Drug · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Ovarian Cancer
Interventions
filgrastim, peripheral blood stem cell transplantation, indium In 111 monoclonal antibody MN-14, yttrium Y 90 monoclonal antibody MN-14
Biological · Procedure · Radiation
Lead sponsor
Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
3
States / cities
Belleville, New Jersey • Paterson, New Jersey • Philadelphia, Pennsylvania
Conditions
Leukemia
Interventions
Filgrastim, Busulfan, Cyclophosphamide, Cyclosporine, Decitabine (DAC), Methotrexate, Methylprednisolone, Tacrolimus, Allogeneic Bone Marrow Transplantation, Peripheral Blood Stem Cell Transplantation
Biological · Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2002
U.S. locations
1
States / cities
Houston, Texas
Conditions
Fanconi Anemia
Interventions
Anti-Thymocyte Globulin, Cyclophosphamide, Fludarabine, Hematopoietic Stem Cell Transplantation, Methylprednisolone, Filgrastim, Cyclosporine, Mycophenolate Mofetil
Biological · Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 59 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
HER-2/neu peptide vaccine, sargramostim, rintatolimod
Biological · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Multiple Myeloma, Plasma Cell Leukemia
Interventions
ARRY-520, KSP(Eg5) inhibitor; intravenous, Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous, Dexamethasone, steroid; oral
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
5
States / cities
Atlanta, Georgia • Detroit, Michigan • Philadelphia, Pennsylvania + 2 more
Conditions
Lymphoma, Non-Hodgkin, HIV Infections
Interventions
Bleomycin sulfate, Vincristine sulfate, Doxorubicin hydrochloride, Cyclophosphamide, Allopurinol, Methotrexate, Cytarabine, Leucovorin calcium, Sargramostim, Dexamethasone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1996
U.S. locations
22
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 13 more
Completed Phase 2 Interventional Results available

Sargramostim Use in COVID-19 to Recover Patient Health

NCT04707664
Conditions
Covid19, SARS-CoV Infection
Interventions
Sargramostim, Placebo
Drug
Lead sponsor
Partner Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
34
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Canoga Park, California + 30 more
Conditions
Chronic Lymphocytic Leukemia
Interventions
GM-K562 vaccine, stem cell transplantation
Biological · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Glioblastoma
Interventions
Human CMV pp65-LAMP mRNA-pulsed autologous DCs containing GM CSF, Temozolomide, Tetanus-Diphtheria Toxoid (Td), GM-CSF, 111-Indium-labeling of Cells for in vivo Trafficking Studies
Biological · Drug
Lead sponsor
Mustafa Khasraw, MBChB, MD, FRCP, FRACP
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Completed Phase 1Phase 2 Interventional Results available

ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma

NCT01592045
Conditions
Neuroblastoma
Interventions
ch14.18 -NCI, ch14.18-UTC, Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), Aldesleukin (IL-2), Isotretinoin
Biological · Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
Up to 8 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 10 more
Conditions
Hodgkin's Lymphoma
Interventions
Panobinostat, Ifosfamide, Mesna, Carboplatin, Etoposide, Pegfilgrastim
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Houston, Texas
Conditions
Critical Injury (Trauma) in Children
Interventions
GM-CSF
Drug
Lead sponsor
Mark Hall
Other
Eligibility
1 Year to 17 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
8
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Detroit, Michigan + 5 more
Conditions
Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ, Lymphoma, Thrombocytopenia
Interventions
Rituxan, Cyclophosphamide, Etoposide, Etoposide phosphate, Carboplatin, Sodium thiosulfate, Neupogen, Neulasta, Cytarabine
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Months to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
2
States / cities
Cincinnati, Ohio • Portland, Oregon
Conditions
Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
filgrastim, sargramostim, cyclophosphamide, melphalan, autologous bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Milwaukee, Wisconsin